Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION
• To assess the efficacy of anidulafungin and caspofungin with respect to the overall global response (clinical and microbiological success) at the EOT in subjects with a confirmed diagnosis of deep t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer (Canada)
MAJ Il y a 4 ans
Effect of pregabalin in acute post-operative pain and functional recovery for laparoscopic cholecystectomy
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc. 235 East 42nd street – New York – 10017 NY - USA
MAJ Il y a 4 ans
A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER
To demonstrate that the combination of sunitinib plus capecitabine is superior to capecitabine monotherapy in prolonging the progression-free survival (PFS) for ABC patients
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd
MAJ Il y a 4 ans
Double-blind, parallel-group, randomized, study of the efficacy and safety of continuous use of celecoxib vs the “usual use” of celecoxib in the treatment of subjects with chronicosteoarthritis of the hip or knee who require an anti-inflammatory medication for control of their pain
To determine whether continuous use over a 6-month period of celecoxib 200 mg per day is more effective than intermittent use of celecoxib 200 mg per day in preventing spontaneous OA flares.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 4 ans
A study to measure pretection (antibody response) and safety against representative strains causing a high proportion of disease (Meningococcal Group B) in healthy subject aged between 12 and <19 years
Primary Immunogenicity Objective • To describe the immune response, relative to baseline status, following receipt of Bexsero as measured by hSBA performed with a panel of MnB test strains assessed ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
MAJ Il y a 4 ans
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN)
The primary objective of this trial is to evaluate the efficacy of Genotropin® treatment on height velocity SDS in short SGA children starting treatment at an age of 24-30 months as compared to untrea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd
MAJ Il y a 4 ans
A randomised, double-blind, parallel group trial to assess the variability and treatment effect size for a Neuropathic Pain offset design
To estimate the difference in average daily pain score (ADPS) after 4 weeks in patients maintained on the ‘standard’ dose of gabapentin compared to those on a reduced dose of gabapentin. To estimate t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
MAJ Il y a 4 ans
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS
To evaluate the efficacy of 20 mg QD and 5 mg QD of CP-945,598 given for 48 weeks in the treatment of NASH.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 4 ans
A 15-WEEK CLINICAL STUDY TO DETERMINE THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF PF-06649751 IN PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE UN ESTUDIO CLÍNICO DE 15 SEMANAS PARA DETERMINAR LA EFECTIVIDAD, SEGURIDAD Y TOLERABILIDAD DE PF-06649751 EN PACIENTES CON FLUCTUACIONES MOTORAS POR ENFERMEDAD DE PARKINSON
- To evaluate the effect on motor symptoms of PF-06649751 administered once daily as adjunctive treatment with stable doses of L-Dopa in Parkinson's disease. - To determine the therapeutic window for ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Ltd
MAJ Il y a 4 ans
A double-blind (third party open), placebo-controlled, parallel group, multiple dose study to investigate the safety, toleration and pharmacokinetics of [S,S]-Reboxetine in young and elderly healthy volunteers
To investigate the safety and toleration of multiple oral doses of (+)-[S,S]-RBX administeredonce daily in an extended release formulation in young and elderly volunteers. To investigate the steady ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
13
14
15
16
17
18
19
20
21
22
Suivant